Fengyan Jin
Clinical trials sponsored by Fengyan Jin, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tailored therapy could boost outcomes in elderly myeloma patients Results expected Sep 2026 (estimated)
- New risk score could tailor therapy for aggressive myeloma Results expected Sep 2027 (estimated)